Introduction

BioGAL is a market-driven developer of drug applications for cancer.
The Company has patented (PCT, pending) the use of  Erythropoietin (Epo) against Multiple Myeloma(MM), an incurable hematological cancer of plasma cells. Clinical observations in human patients and research in animals have shown that Epo could be highly effective in MM. BioGAL is also examining the effect of Epo on additional potential cancer types.

Published Articles:
Mittelman M., Neumann D., Peled A., Kanter P. and Haran- Ghera N. (2001).Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. PNAS, vol. 98 : 9 . 5181 - 5186

In order to read the article you need to
download the "Adobe Reader".

Back to top